MFS Investment Management, which claims to have invented the mutual fund in 1924, owned about 20.9 million shares, or an 8% stake, as of March 23. In a YY regulatory filing, MFS said it now owns about 27.2 million shares, according to regulatory filings.
With STJ shares trading at $37.88 apiece as of about 11;40 today, Boston-based MFS’s stake is worth about $1.03 billion.
The Durham, N.C.-based spinout, which employs about 500 workers, originated as Smith & Nephew’s biologics & clinical therapies division in 2008. It posts annual sales of about $240 million, according to a press release.
Smith & Nephew said Bioventus employees outside the U.S. will stay on with the parent company, which will distribute Bioventus products until the business can be transferred to Bioventus. The company sells the Exogen ultrasound bone healing system, the Supartz hyaluronic acid therapy for knee osteoarthritis and the Durolane joint fluid treatment.
"Bioventus will be aggressively seeking to expand its product portfolio, focusing on the orthopedic biologics space," according to the release.
Smith & Nephew also said it acquired negative-pressure wound therapy maker Kalypto Medical for an undisclosed amount.
Kerberos Proximal Solutions puts Rinspiration on the auction block
Kerberos Proximal Solutions said it plans to put its Rinspiration thrombectomy platform on the auction block during the upcoming EuroPCR conference.
NeuroLogica helps develop 1st mobile stroke ambulance
NeuroLogica said it co-developed the world’s first mobile stroke ambulance with Germany’s Meytec GmbH using Meytec’s telemedicine solutions and NeuroLogica’s portable CereTom CT scanner.
- OrthoSensor adds $15M in Series B round
- Medical Care Technologies inks reserve equity deal with AGS Capital
- Stereotaxis aims to raise $18.5M in private placements
- Monteris Medical lands $9M round